A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.

Anna V Tinker,Neesha C Dhani,Prafull Ghatage,Deanna McLeod,Vanessa Samouëlian,Stephen A Welch,Alon D Altman

Therapeutic advances in medical oncology（2023）

引用 2|浏览19

暂无评分

摘要

Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.

查看译文

关键词

advanced,biomarker selection,endometrial cancer,immune checkpoint inhibitors,metastatic,pretreated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要